Valuation : GlaxoSmithKline Pakistan Limited

Market Cap 10TCr 37Cr 32Cr 30Cr 27Cr 51Cr 3.5TCr 51Cr 354.78Cr 137.67Cr 1.8TCr 139.26Cr 136.22Cr 5.79TCr P/E 2026 *
9.73x
P/E 2027 * 8.08x
Enterprise Value 10TCr 37Cr 32Cr 30Cr 27Cr 51Cr 3.5TCr 51Cr 354.78Cr 137.67Cr 1.8TCr 139.26Cr 136.22Cr 5.79TCr EV / Sales 2026 *
1.49x
EV / Sales 2027 * 1.38x
Free-Float
16.89%
Yield 2026 *
5.58%
Yield 2027 * 6.44%
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Chief Financial Officer, Effective October 15, 2026 CI
04/09 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Yousuf Vohra as Finance Director, Effective October 15, 2026 CI
28/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Muhammad Masood Ahmed Khan to Executive Director, Effective August 28, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
25/08 GlaxoSmithKline Pakistan Limited Interim Cash Dividend for the Half Year Ended June 30, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Appoints Umair Majeed as Interim/Acting Chief Financial Officer, Effective from July 30, 2026 CI
03/08 GlaxoSmithKline Pakistan Limited Announces Appointment of Hasham Ali Baber as Non-Executive Director, Effective July 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
1 day-0.02%
1 week-4.65%
Current month-3.57%
1 month-8.57%
3 months-7.94%
6 months-0.81%
Current year-17.13%
1 week 321
Extreme 321
337.6
1 month 321
Extreme 321
351.95
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 69.21
Extreme 69.21
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%-4.65%-20.79%+361.11% 37Cr
-0.88%-2.15%+58.05%+105.26% 1,02400Cr
-1.15%+2.68%+54.25%+74.19% 66TCr
-1.44%+0.38%+20.65%+76.13% 45TCr
+0.14%-0.47%+30.20%+41.44% 35TCr
-1.33%+4.72%+24.62%+48.58% 30TCr
-1.15%+0.30%-0.69%+13.20% 25TCr
-1.55%+1.11%+54.15%+75.59% 24TCr
-0.88%+1.15%-14.60%-54.96% 21TCr
-0.15%+3.65%+31.24%+103.39% 19TCr
Average -0.84%+0.78%+23.71%+84.39% 36.79TCr
Weighted average by Cap. -0.96%+0.62%+37.62%+68.04%

Financials

2026 *2027 *
Net sales 6.88TCr 25Cr 21Cr 20Cr 18Cr 34Cr 2.34TCr 34Cr 237.33Cr 92Cr 1.2TCr 93Cr 91Cr 3.87TCr 7.46TCr 27Cr 23Cr 22Cr 20Cr 37Cr 2.54TCr 37Cr 257.21Cr 100Cr 1.3TCr 100.96Cr 99Cr 4.2TCr
Net income 1.05TCr 3.78Cr 3.25Cr 3.06Cr 2.8Cr 5.23Cr 357.05Cr 5.25Cr 36Cr 14Cr 183.19Cr 14Cr 14Cr 590.16Cr 1.24TCr 4.48Cr 3.85Cr 3.63Cr 3.31Cr 6.19Cr 422.76Cr 6.21Cr 43Cr 17Cr 216.9Cr 17Cr 16Cr 698.77Cr
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
04/26/04 PKR 323.01 -0.02% 1,22,258
03/26/03 PKR 323.08 -0.80% 1,18,223
02/26/02 PKR 325.69 -1.92% 1,46,924
01/26/01 PKR 332.08 -0.86% 6,46,217
31/26/31 PKR 334.97 -1.12% 3,44,884
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
323.01PKR
Average target price
510.00PKR
Spread / Average Target
+57.89%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!